DelistingJul 31, 2026, 05:07 PM
Humacyte Receives Nasdaq Delisting Notice for Low Stock Price
AI Summary
Humacyte, Inc. received a notice from Nasdaq on July 31, 2026, indicating that its common stock failed to meet the minimum $1.00 bid price requirement for continued listing. The stock traded below $1.00 for 30 consecutive business days. The company has an initial period of 180 calendar days, until January 27, 2027, to regain compliance by maintaining a closing bid price of $1.00 or more for at least 10 consecutive business days. The notice does not immediately affect the stock's listing or the company's operations, and Humacyte plans to monitor its stock price and explore options to achieve compliance.
Key Highlights
- Humacyte received a Nasdaq notice on July 31, 2026, for non-compliance with the minimum bid price rule.
- The company's common stock bid price closed below $1.00 for 30 consecutive business days.
- Humacyte has 180 calendar days, until January 27, 2027, to regain compliance.
- To comply, the stock must close at $1.00 or more for a minimum of 10 consecutive business days.
- The notice has no immediate effect on the stock's listing or the company's business operations.
- Humacyte intends to monitor the stock price and consider options to achieve compliance.
Price Impact
More from HUMA